Research programme: diagnostic imaging - MallinckrodtAlternative Names: Diagnostic imaging research programme - Mallinckrodt
Latest Information Update: 16 Jul 2016
Price : $50 *
At a glance
- Originator Mallinckrodt Inc.; Mallinckrodt Medical
- Developer Mallinckrodt Inc.
- Class Peptide diagnostics
- Mechanism of Action Neurotensin receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer(Diagnosis) in USA
- 13 Aug 2003 Preclinical trials in Diagnostic imaging in USA (unspecified route)